Crossmark

457 Efficacy of pembrolizumab as cross-line treatment in advanced non-small cell lung cancer: a multi-center non-interventional study from China

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0457

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Ruan, Kexin

Zheng, Jing

Zhou, Jianying

Li, Yuping

Lv, Xiaodong

Wu, Xiaoyu

Ding, Liren

Zhou, Jianya
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04153097 at ClinicalTrials.gov

Documents that mention this clinical trial

457 Efficacy of pembrolizumab as cross-line treatment in advanced non-small cell lung cancer: a multi-center non-interventional study from China
https://doi.org/10.1136/jitc-2022-sitc2022.0457